Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

View Full Paper
Ask AI
Bookmark
Share

Authors

XQXiaoyu QuSJShahanawaz JiwaniHEHarry P. Erba

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CGAT improves diagnostic yield in AML and MDS, suggesting better risk stratification for patients.

Key Points

  • Assess the impact of chromosome genomic array testing (CGAT) on diagnostic yield and risk stratification in AML and MDS patients.
  • Included newly diagnosed AML and MDS patients from the NCI myeloMATCH trial.
  • CGAT performed using CytoScan HD Array and combined with FISH for specific translocations.
  • Compared CGAT results with karyotype and FISH to evaluate unique findings in diagnostics.
  • CGAT demonstrated a diagnostic yield of 67% compared to 59% for karyotype and 50.5% for FISH.
  • In 77.3% of cases with complete data, at least one test indicated clonal aberrations.
  • CGAT findings could alter risk stratification in 11.4% of patients overall.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9fbhttps://doi.org/10.1182/blood-2025-3501
View Full Paper
Ask AI
Bookmark
Share